Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
US-2018258161-A1 · Sep 13, 2018 · US
Antibody molecules to C5AR1 and uses thereof
US12415865B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12415865-B2 |
| Application number | US-202318478846-A |
| Country | US |
| Kind code | B2 |
| Filing date | Sep 29, 2023 |
| Priority date | Jan 13, 2020 |
| Publication date | Sep 16, 2025 |
| Grant date | Sep 16, 2025 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Antibody molecules that specifically bind to C5aR1 are disclosed. The antibody molecules can be used to treat, prevent, and/or diagnose disorders, such as ANCA-vasculitis.
First claim
Opening claim text (preview).
The invention claimed is: 1. A nucleic acid molecule comprising a nucleotide sequence encoding an antibody molecule that binds to complement component 5a receptor 1 (C5aR1), wherein the antibody molecule comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH comprises an HCDR1 comprising an amino acid sequence of SEQ ID NO: 612, an HCDR2 comprising an amino acid sequence of SEQ ID NO: 732, and an HCDR3 comprising and amino acid sequence of SEQ ID NO: 852, and wherein the VL comprises an LCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acid residues from SEQ ID NO: 672, an LCDR2 comprising an amino acid sequence of SEQ ID NO: 792, and an LCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acid residues from SEQ ID NO: 912. 2. A host cell comprising the nucleic acid molecule of claim 1 .
Assignees
Inventors
Classifications
Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title
multispecific · CPC title
comprising antibodies · CPC title
Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity · CPC title
Single chain antibody (scFv) · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12415865B2 cover?
- Antibody molecules that specifically bind to C5aR1 are disclosed. The antibody molecules can be used to treat, prevent, and/or diagnose disorders, such as ANCA-vasculitis.
- Who is the assignee on this patent?
- Visterra Inc
- What technology area does this patent fall under?
- Primary CPC classification C07K16/2896. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Sep 16 2025 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 12 related publications on this page (citations in our corpus or others sharing the same primary CPC).